Title:
IRAK4 DEGRADATION AGENT AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/094190
Kind Code:
A1
Abstract:
The present invention relates to use of compounds of formula I and formula II, and specifically relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and/or preventing an inflammatory or immune disease. The present invention relates to use of compound A1-A52, B1-B5, or C1-C36 in the preparation of a drug for treating and/or preventing diseases such as rheumatoid arthritis, atopic dermatitis, hidradenitis suppurativa, vitiligo, dermatomyositis, alopecia areata, urticaria, multiple myositis, an interstitial lung disease, systemic lupus erythematosus, systemic sclerosis, and psoriasis.
More Like This:
Inventors:
FENG YAN (CN)
YE ZHENGQING (CN)
LI SHIQIANG (CN)
DING CHENLI (CN)
CHEN HAIJI (CN)
XU JUAN (CN)
WANG QIAO (CN)
WEI HONG (CN)
XIE SHUCHEN (CN)
YE ZHENGQING (CN)
LI SHIQIANG (CN)
DING CHENLI (CN)
CHEN HAIJI (CN)
XU JUAN (CN)
WANG QIAO (CN)
WEI HONG (CN)
XIE SHUCHEN (CN)
Application Number:
PCT/CN2023/129712
Publication Date:
May 10, 2024
Filing Date:
November 03, 2023
Export Citation:
Assignee:
SHANGHAI LEADINGTAC PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D471/10; A61K31/395; A61K31/513; A61P37/02; A61P37/06; C07D239/22; C07D401/14; C07D403/12
Domestic Patent References:
| WO2022028547A1 | 2022-02-10 | |||
| WO2022088551A1 | 2022-05-05 | |||
| WO2021213287A1 | 2021-10-28 |
Foreign References:
| CN115710274A | 2023-02-24 |
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: